免疫学应答与慢性乙型肝炎血清学转换的关系.pdfVIP

·10990 · 中华临床医师杂志( 电子版)2013 年12 月第7 卷第23 期 Chin J Clinicians(Electronic Edition),December 1,2013,Vol.7,No.23 ·综述· 免疫学应答与慢性乙型肝炎血清学转换的关系 李智彬 刘永明 苏何玲 钟彦伟 【摘要】 乙型肝炎病毒 （HBV ）感染是全球性的卫生问题，每年有将近100 万人死于HBV 感染所致 的肝衰竭等肝脏疾病。大部分的慢性乙型肝炎（CHB ）患者经过抗病毒治疗后可以达到持久的免疫，小部 分的还可以达到临床治愈。理想的抗病毒治疗过程一般经过三个重要转折点，分别是 HBV DNA 转阴， HBeAg 血清学转换及HBsAg 血清学转换。长效干扰素治疗的患者只有40%左右的患者出现HbeAg 血清学 转化，因此，对CHB 患者或许可采取调整患者免疫功能从而达到临床治愈。 【关键词】 肝炎，乙型, 慢性； HBeAg 血清学转换； HBsAg 血清学转换； 免疫 * The relationship between immune response and chronic hepatitis B seroconversion LI Zhi-bin , LIU * Yong-ming, SU He-ling, ZHONG Yan-wei. Guilin Medical University, Guilin 541000, China Corresponding author: ZHONG Yan-wei, Email: zhongyanwei302@163.com 【Abstract 】 HBV infection is a global healthy question. Every year almost one million people are dead from HBV related diseases, such as hepatic failure or liver cirrhosis. The majority of the chronic hepatitis B (CHB) patients, who had received antiviral therapy, will get the ability of antiviral persistence immunity while the minority of these patients came up to the standard of clinical cure. The ideal process of antiviral therapy has three important turning points, including HBV DNA seroconversion, HBeAg seroconversion and HBsAg seroconversion. However, only 40% patients who received pegylated interferon therapy have the effect of HBeAg seroconversion. Thus, the CHB patients may achieve clinical cure by regulating their immune functions. 【Key words 】 Hepatitis B, chronic; HBeAg seroconversion; HBsAg seroconversion; Immunity 乙型肝炎病毒（hepatitis B virus ，HBV ）感染是全球性的公 奠定基础。 共卫生问题，全球有约20 亿人曾感染过HBV ，其中3.5 亿人为